Hugo Boss (OTC:BOSSY) Stock, Quote.Headers.trade-ideas

Hugo Boss is a German-based menswear apparel brand operating in the premium segment through its two brands, Boss and Hugo. The brand was founded in 1924 and initially focused on uniforms. After World War II and the death of the founder, the company shifted focus to men's suits. The company is globally present with 61% of revenue generated in the European market, 23% in the Americas, 14% in Asia-Pacific, and less than 3% from licenses. It generates over 50% of sales through its own retail with over 1,400 stores globally.

Earnings

News

Guidance

General

BOSSY

Hugo Boss Posts 27% Revenue Growth In FY22; Warns Of Slower Growth In FY23

Penny Stocks

Small Cap

$BTC

$ETH

AAPL

AMZN

BABA

BDRBD

BDRBF

JDSPY

MRNA

MSFT

RYCEY

SDIPF

TSLA

VWAGY

CNBC

Moderna To establish New Vaccine Facility In Britain

Benzinga Before The Bell: Executive Shakeup At Amazon, Boeing Supply Chain Warning, Apple&#39;s Tim Cook Says &#39;Stay Tuned&#39; On AR/MR And Other Top Financial Stories Wednesday, June 22

British Retailer Frasers Boosts Investment In Hugo Boss

Hugo Boss AG

<a href="https://www.bloomberg.com/news/articles/2024-09-25/olympics-caterer-sodexo-is-said-to-weigh-acquisition-of-aramark?embedded-checkout=true" title="https://www.bloomberg.com/news/articles/2024-09-25/olympics-caterer-sodexo-is-said-to-weigh-acquisition-of-aramark?embedded-checkout=true">https://www.bloomberg.com/news/articles/2024-09-25/olympics-caterer-sodexo-is-said-to-weigh-acquisition-of-aramark?embedded-checkout=true</a>

ARMK

SDXAY

Bloomberg Reported Sodexo Weighs Acquisition Of Aramark

Billionaire Chamath Palihapitiya shared his thoughts on immigration and how the media portrays Donald Trump during a sit-down interview with Joe Rogan, who remains one of the <a href="https://www.benzinga.com/general/entertainment/23/11/36004998/joe-rogan-tops-spotifys-2023-podcasts-list-once-again-deal-likely-to-expire-in-2024-a-major">most popular podcasters.</a>
Chamath On Immigration: The topic of immigration is one of the top voter issues in <a href="https://www.benzinga.com/topic/2024-election">the 2024 election </a>and Palihapitiya believes whoever wins the election will have to act on the crisis.
"Both of them will probably have to act," Palihapitiya <a href="https://www.youtube.com/watch?v=we-mZ-KTe-8">said</a> on episode #2206 of &#8220;The Joe Rogan Experience.&#8221; 
Palihapitiya said he likes to give both candidates the benefit of the doubt on the issue, despite Rogan criticizing the current Biden administration, which includes Vice President Kamala Harris, not doing enough.
"I think that Donald Trump has had a clearer view of this issue for much far longer. I think that Kamala has had to shift her position."
The billionaire investor said the two political sides likely differ about how to handle immigration and foreign policy.
Rogan said there are pros and cons of immigration, citing the need for cheap labor. The podcast host questions if there is an incentivized effort to bring people into the country illegally and buying the vote, as he says Elon Musk has alleged.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent092524">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Chamath on Media: When it comes to how Donald Trump is portrayed by the media, Palihapitiya said the media lies about him, including a comment about "very fine people" said during a speech in Charlottesville.
"I met him and spent time with him," Palihapitiya said of Trump.
The billionaire investor said Trump was kind and "he talks to you," which he wasn't expecting due to the media's portrayal of the former president.
"I think the media really gets tilted."
Rogan said Trump&#8217;s flaws are nothing compared to how the media depicts him, which Palihapitiya agreed with and said Trump's flaws are well described already.
The media's depiction of Trump could have a negative impact, the investor added.
"The trust in the mainstream media is the lowest it has ever been."
Palihapitiya said he's also had "lunch with Kamala" and said she was very kind and a "very nice person."
Musk <a href="https://x.com/elonmusk/status/1839043088833995194">shared </a>a clip on Palihapitiya and Rogan discussing the media's depiction of Trump and said that they had "good points."
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/08/40306405/after-trump-slams-joe-rogan-for-rfk-jr-endorsement-podcast-host-walks-back-remarks-saying-im-not-the">After Trump Slams Joe Rogan For RFK Jr Endorsement, Podcast Host Walks Back Remarks, Saying &#8216;I&#8217;m Not The Guy To Get Political Information From&#8217;</a></li>
</ul>
Photo: Featureflash Photo Agency on Shutterstock

Entertainment

Politics

Media

Chamath Palihapitiya Tells Joe Rogan That Trump, Harris Have To Act On The Border: 'I Think That Donald Trump Has Had A Clearer View Of This Issue'

Toria Lyttle, a 43-year-old mother from Newtownards, in Northern Ireland, turned to medical marijuana to manage her severe migraines, which have plagued her since <a href="https://www.benzinga.com/markets/cannabis/23/12/36228666/the-kids-are-alright-government-study-finds-teen-cannabis-use-holds-steady-despite-increased-sta">childhood. </a>
With monthly prescription costs reaching up to 350 pounds sterling ($366), Toria's case underscores the ongoing challenges of accessing alternative treatments for chronic pain in the UK, <a href="https://www.wfxg.com/news/health-news-now/mom-says-cannabis-cured-migraines-she-s-had-for-30-years/article_507b97f9-28a9-5d62-8377-7cff579f533a.html">reported</a> Fox 54 News.
See Also: <a href="https://www.benzinga.com/markets/cannabis/23/04/31728661/can-marijuana-help-with-migraines-ms-related-chronic-pain-new-clinical-guidelines-are-here">Can Marijuana Help With Migraines? MS-Related Chronic Pain? New Clinical Guidelines Are Here</a>
<h3 class="wp-block-heading">Living With Chronic Migraines</h3>
Toria has battled migraines since she was nine. The situation became worse when doctors diagnosed her with a benign brain tumor three years ago.
Despite the diagnosis, her migraines persisted, leading to years of disrupted sleep, pain and an inability to live her life fully. "I've lived with these awful migraines my whole life, but no one could ever tell me why I suffered with them," Toria said.
Before turning to medical cannabis, she had been prescribed various painkillers, none of which eased her symptoms, often making her feel worse. Desperate for a solution, Toria approached her doctor in September 2023 about trying medical marijuana.
<h3 class="wp-block-heading">Turning To Medical Cannabis</h3>
After consulting with a specialist at the private medical cannabis clinic Alternaleaf, Toria received a prescription for 30 grams of THC-containing cannabis each month. She now vapes two to four doses daily, depending on the severity of her symptoms. She says the change has been transformative.
"Medicinal cannabis has allowed me to live again," she said. "It has lightened my world because I don't feel terrified about the next migraine anymore and it's much fairer for the people around me, too, because my temper is so much better."
Though the cannabis has not eliminated her pain entirely, it has significantly improved her condition, allowing her to sleep through the night and function during the day. 
"It hasn't taken the pain away completely, but I can manage it now," she added.
<h3 class="wp-block-heading">Cannabis Study Confirms Efficacy For Migraine Sufferers</h3>
Meanwhile, research presented at the 2023 American Headache Society Annual Meeting validates the effectiveness of cannabis for migraines, echoing the life-changing relief experienced by Lyttle. 
The <a href="https://www.benzinga.com/markets/cannabis/23/06/32914574/vaporized-cannabis-a-promising-migraine-treatment-suggests-study-at-american-headache-society-me">study</a>, led by Dr. Nathaniel Schuster, found that a combination of THC and CBD significantly reduced migraine symptoms within two hours of use.
Patients were randomly assigned to either tetrahydrocannabinol (THC) 6%, a mix of THC and cannabinoid (CBD) 11%, CBD 11% and placebo cannabis.
&#8220;The doses that we used are probably lower than what a lot of people out there are using on their own, and higher doses do not necessarily mean more effective,&#8221; Schuster said. &#8220;The highness patients were having in the study was not very high, probably somewhere between a 2-4 out of 10 on subjective highness."
Migraines&nbsp;affect&nbsp;47 million Americans,&nbsp;75%&nbsp;of whom are women. Although a splitting&nbsp;headache is one symptom, migraine attacks can include visual disturbances, nausea, extreme light and sound sensitivity, brain fog and debilitating pain.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/07/39843370/tevas-migraine-treatment-found-effective-for-children-as-young-as-6">Teva&#8217;s Migraine Treatment Found Effective For Children As Young As 6</a></li>
</ul>
Cover image made with AI.

Cannabis

Health Care

Markets

Chronic Migraines And Cannabis: How One Mom Found Relief After A Lifetime Of Pain

Florida Gov. <a href="https://www.benzinga.com/topic/ron-desantis">Ron DeSantis</a> (R) faces a public relations lashing for leveraging a taxpayer-funded advertisement to influence voters against the marijuana legalization measure, known as <a href="https://www.benzinga.com/markets/cannabis/24/04/38034138/florida-supreme-court-approves-cannabis-legalization-proposal-for-november-election-in-blow-to-d">Amendment 3</a>, which will be decided upon in the <a href="https://www.benzinga.com/topic/2024-election">November 2024 election</a>. 
The ad, produced by the Florida Department of Transportation, warns against the dangers of driving under the influence of cannabis.
In the middle of the 30-second video warning viewers not to drive high, the narrator says, "DUI crashes increase in states with legalized marijuana, putting everyone at risk."
<h1 class="wp-block-heading">Outrage Ensues</h1>
The ad sparked anger among advocates with Smart &amp; Safe Florida, the campaign that helped put Amendment 3 on the ballot. The campaign called the DeSantis-backed Vote No on 3 political committee of using state resources to amplify an opposition talking point at a lower cost by channeling the message through a government agency.
The campaign sent cease and desist letters to about 50 news stations across Florida. In it, the group condemns the use of taxpayer money to disseminate what they call a "ruse to obtain the highly discounted rates" for airing PSAs.
"Florida law demands that campaigns be operated in the sunshine," the Smart &amp; Safe letter said. "Accepting taxpayer funds to broadcast State Propaganda under the guise of a public service announcement — and at an anticompetitive and severely discounted rate — should not be countenanced."
The campaign also criticized the refusal of TV stations to air what Smart &amp; Safe called a &#8220;politically neutral&#8221; alternative, accusing them of participating in a scheme to secure discounted rates for the ad. The news was&nbsp;<a href="https://subscriber.politicopro.com/article/2024/09/florida-pot-legalization-psa-00180788?source=email" target="_blank" rel="noreferrer noopener">first reported by Politico</a>&nbsp;on Tuesday.
Suggesting a direct link between marijuana legalization and increased impaired driving is seen as misleading, with some research indicating mixed results on the matter. Federal reports have also stated that the impact of cannabis on driving is not yet fully understood.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/09/41016011/florida-cannabis-ballot-nfls-ricky-williams-backs-legalization-new-ad-hypocrisy-of-alcohol-vs-ma">Florida Cannabis Ballot: NFL&#8217;s Ricky Williams Backs Legalization, New Ad &#8216;Hypocrisy Of Alcohol Vs. Marijuana&#8217;</a>
<h1 class="wp-block-heading">GOP and Dem Politicians Weigh In</h1>
The controversy has drawn further attention from political figures like <a href="https://www.benzinga.com/topic/nikki-fried">Nikki Fried,</a> chair of the Florida Democratic Party, who criticized DeSantis for using public funds to campaign against not only the marijuana legalization initiative but a separate reproductive rights measure, known as Amendment 4.
Meanwhile, <a href="https://www.benzinga.com/markets/cannabis/24/09/40969689/desantis-urges-gop-to-oppose-cannabis-legalization-as-party-splits-over-trump-marijuana-endorsem">Jeff Brandes</a>, a former Republican state senator, warned that the governor&#8217;s actions set a dangerous precedent, suggesting that such use of public funds may not be permissible under Florida&#8217;s budget.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/09/40969689/desantis-urges-gop-to-oppose-cannabis-legalization-as-party-splits-over-trump-marijuana-endorsem">DeSantis Urges GOP To Oppose Cannabis Legalization As Party Splits Over Trump Marijuana Endorsement</a></li>
</ul>
Photo: Benzinga&nbsp;edit of image by&nbsp;<a href="https://unsplash.com/fr/@mrbrodeur?utm_source=unsplash&amp;utm_medium=referral&amp;utm_content=creditCopyText" target="_blank" rel="noreferrer noopener">Matthew Brodeur</a>&nbsp;on&nbsp;<a href="https://unsplash.com/photos/qcCPIhhdgTw?utm_source=unsplash&amp;utm_medium=referral&amp;utm_content=creditCopyText" target="_blank" rel="noreferrer noopener">Unsplash</a>&nbsp;and Wikimedia Commons

Government

Regulations

DeSantis Provokes Outrage Over Taxpayer-Funded Ads Linking Marijuana Legalization To Car Crashes

Sales of single-family homes fell last <a href="https://www.benzinga.com/real-estate/24/06/39465243/u-s-home-sales-decline-for-third-month-as-record-prices-pose-persistent-affordability-challenges-dur">month from July </a>but rose from a year ago as mortgage rates kept falling.
New single-family home sales fell 4.7% in August from the prior month to an annualized rate of 716,000, according to estimates released on Wednesday by the U.S. Census Bureau and the Department of Housing and Urban Development.
That was up 9.8% from an annualized rate of 652,000 home sales in August 2023.
The latest month-over-month decline was in contrast to a 10.3% jump in single-family home sales from June to July.
Single-family home sales fell the most from July to August in the West, falling 17.8% to an annualized rate of 152,000 in that region.
Read Also: <a href="https://www.benzinga.com/real-estate/24/06/39398524/home-sales-suffer-third-worst-month-in-the-last-10-years">Home Sales Suffer Third Worst Month In The Last 10 Years</a>
Sales of all homes, which also included condominiums, townhomes and co-ops, slipped 2.5% from July to a seasonally adjusted annual rate of 3.86 million in August, according to latest figures from the National Association of Realtors (NAR). Year-over-year sales for August declined 4.2% from 4.03 million in August 2023.
"Home sales were disappointing again in August, but the recent development of lower mortgage rates coupled with increasing inventory is a powerful combination that will provide the environment for sales to move higher in future months," NAR chief economist Lawrence Yun said.
"The home-buying process, from the initial search to getting the house keys, typically takes several months."
The interest rate on a 30-year mortgage fell to a <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/41024067/mortgage-demand-soars-as-fed-interest-rate-cut-fuels-housing-market-revival-next-sp">two-year low of 6.13%</a>, a week after the Federal Reserve cut interest rates by 50 basis points to mark the first Fed rate cut in four years.
Price Action: Lennar Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEN#NYSE">LEN</a>), one of the largest homebuilders with a market cap of $49.5 billion, slipped 1.29% to close Wednesday at $181.86.
<ul>
<li>IShares U.S. Home Construction ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ITB#BATS">ITB</a>) slipped 1.71%</li>
<li>Direxion Daily Homebuilders &amp; Supplies Bull 3X Shares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NAIL#NYSE">NAIL</a>) fell 4.94%</li>
<li>AdvisorShares Gerber Kawasaki ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GK#NYSE">GK</a>) went up 0.17%</li>
</ul>
Read Now: 
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/07/39909262/us-home-sales-see-sharpest-monthly-decline-in-1-5-years-as-record-high-prices-keep-buyers-on-the-s">US Home Sales See Sharpest Monthly Decline In 1.5 Years As Record High Prices Keep Buyers On The Sideline</a></li>
</ul>
Photo: Floridastock via Shutterstock

REIT

iShares Dow Jones US Homenstruction Index Fund

NAIL

New US Single-Family Home Sales Fall From Prior Month — But Are Up From A Year Ago As Mortgage Rates Decline

BofA Securities says U.S. consumers are focused on value and sees Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) and Walmart Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) well-positioned in the e-commerce industry to reap the benefits heading <a href="https://www.benzinga.com/news/24/09/41023224/top-10-stock-picks-for-the-holiday-boom-adobe-forecasts-unprecedented-e-commerce-sales-this-season">into the holiday season.</a> 
What To Know: On Wednesday, BofA released its 2025 annual e-commerce survey which monitors sector trends, inflections and outlook for the next year. The research firm expects e-commerce to grow its market share during the upcoming holiday season as consumers are drawn to online shopping by convenience, price comparability and a shorter holiday shopping window after Thanksgiving.&nbsp;
The survey revealed 52% of respondents expect to increase their online spending year-over-year, compared to 46% last year. However, 62% of respondents said they are seeking lower prices due to economic changes and uncertainty about the upcoming Presidential election. 
Read Next:<a href="https://www.benzinga.com/news/24/09/41011763/whats-going-on-with-intel-stock"> What&#8217;s Going On With Intel Stock?</a>
Why It Matters: BofA sees retailers offering consumables and value pricing, such as Walmart and Amazon, as best-positioned to gain market share as consumers look for lower prices and price comparability in an uncertain environment. 
Walmart remained the most popular online grocery retailer with 30% of respondents opting for the grocery giant. Amazon saw the highest spending intentions in the survey, with 45% of respondents intending to increase their usage over the next six months.&nbsp;
Sixty-seven percent of respondents reported using Temu, a subsidiary of PDD Holdings, Inc. &#8211; ADR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>), a gain of 13 points year-over-year. However, only 20% intend to increase their Temu usage, down by eight points from last year. 
Overall, BofA forecasts healthy consumer online spending in the upcoming holiday shopping season with a shift from discretionary categories into consumables.&nbsp;
AMZN, WMT, PDD Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Amazon shares closed Wednesday's session down 0.74% at $192.53, Walmart shares rose 0.90% to $81.40 and PDD Holdings shares ended the session 0.12% higher at $113.94. 
Read Also:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40991529/what-happened-with-palantir-stock-today">What Happened With Palantir Stock Today?</a></li>
</ul>
Photo: Jill Wellington from Pixabay

Analyst Color

Movers

Citigourp Global Markets 2% Protected Notes Linked To The Djia

Expect Healthy Online Spending This Holiday Season, Says Analyst: What To Know

Investcorp Credit (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICMB#NASDAQ">ICMB</a>) reported quarterly earnings of $0.09 per share which missed the analyst consensus estimate of $0.13 by 30.77 percent.

Earnings Misses

ICMB

Investcorp Credit Q4 2024 GAAP EPS $0.09 Misses $0.13 Estimate

Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) is one of several companies benefitting from demand for weight loss drugs. The company is also seeing competition in the market including knockoff drugs that it said <a href="https://www.benzinga.com/general/biotech/24/08/40376247/dont-promote-copycat-weight-loss-drugs-amid-improved-supply-eli-lilly-asks-doctors-fda-evaluates">could be unsafe</a>.
What Happened: A recent report says Eli Lilly is seeking medical records of people who took knockoff <a href="https://www.benzinga.com/topic/weight-loss">weight loss drugs.</a>
The request, reported by <a href="https://www.bloomberg.com/news/articles/2024-09-19/lilly-wants-records-from-people-who-took-weight-loss-knockoffs?sref=TBDibEcD">Bloomberg</a>, is being done for safety reasons according to the pharmaceutical company.
Eli Lilly is building a case against businesses that are selling knockoffs of the company's Zepbound and Monjaro. Compounding pharmacies have been capitalizing on Lilly seeing supply constraints and shortages while demand remains high.
Lilly has said that the quality of the compounding pharmacies products are inferior and questions the safety profile of the treatment.
A letter viewed by Bloomberg requested information from a patient who took a Lilly product from a compounded pharmacy.
"We would appreciate if you could complete the enclosed form and sign the Authorization for Release of Medical Information so that we can obtain more details from the treating physician around your experience," the letter says.
Along with items like the letter, Eli Lilly also took out an advertisement in national publications encouraging patients to make sure they are taking the "real product."
Read Also:<a href="https://www.benzinga.com/markets/cannabis/24/09/41033009/can-novo-nordisks-weight-loss-drug-ozempic-help-stem-the-devastating-addiction-crisis-new-resear"> Can Novo Nordisk&#8217;s Weight Loss Drug Ozempic Help Stem The Devastating Addiction Crisis? New Research Says Yes</a>
Why It's Important: Obtaining medical records could be a key in Eli Lilly's battle against compounding pharmacies. The short supply of Lilly and other companies' weight loss drugs helped the argument for a legal loophole that allows compounding of drugs when a supply constraint happens.
If Eli Lilly can prove that the drugs are not as safe and are causing side effects or harm to patients, it could help put a stop to compounding pharmacies. Without proof, Eli Lilly may fall victim to the legal loophole and the issue of soaring demand for its own products.
Eli Lilly <a href="https://www.benzinga.com/general/biotech/24/08/40251130/mounjaro-maker-eli-lillys-bumper-q2-earnings-exceeds-estimates-hikes-outlook-again-on-strong-diab">reported second-quarter </a>revenue of $11.3 billion, up 36% year-over-year. Mounjaro and Zepbound had revenue of $3.1 billion and $1.2 billion, respectively, seeing significant gains in the quarter.
The pharmaceutical company increased its full-year guidance as a result of the second-quarter results and increasing demand for several products.
LLY Price Action: Eli Lilly stock closed Wednesday at $924.56 versus a 52-week trading range of $516.57 to $972.53. Eli Lilly stock is up 56% year-to-date in 2024.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/09/41002452/eli-lillys-early-alzheimers-treatment-donanemab-scores-japanese-approval-its-second-largest-marke">Eli Lilly&#8217;s Early Alzheimer&#8217;s Treatment Donanemab Scores Japanese Approval, Its Second Largest Market</a></li>
</ul>
Photo: Shutterstock

Biotech

Trading Ideas

Eli Lilly Stock Soars In 2024 On Weight Loss Drug Success, Now The Company Wants Medical Records Of Copycat Treatments

Some experts believe Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) products not only help people lose weight and control diabetes, they can help treat the <a href="https://www.benzinga.com/markets/cannabis/24/09/41033009/can-novo-nordisks-weight-loss-drug-ozempic-help-stem-the-devastating-addiction-crisis-new-resear">country&#8217;s addiction crisis.</a> 
The Novo Nordisk chart illustrates two common technical analysis dynamics that <a href="https://www.benzinga.com/quote/NVO">successful traders can use to profit.</a>
As you can see, the $123 level was support for the stock in April. Then it was support again in early August. And after a recent move higher and a reversal, the stock found support around the same level again.
Support can stay intact for an extended time because of investor and trader psychology. It is because there are traders who sold while the stock was at support. But right after they were done selling, the shares rallied.
When this happened, many of these sellers came to regret their decision to get rid of their shares. Some of them decided to buy their shares back. But, they will only do so if they can buy the shares for the same price they were sold.
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="979" height="603" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/25173834/1-26.png" alt="" class="wp-image-566523" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/25173834/1-26.png 979w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/25173834/1-26-300x185.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/25173834/1-26-768x473.png 768w" sizes="(max-width: 979px) 100vw, 979px" /></figure>
Read Also:<a href="https://www.benzinga.com/general/biotech/24/09/41034046/popular-ozempic-may-have-new-use-as-semaglutide-drugs-linked-to-reduced-overdose-risk-in-diabetic"> Popular Ozempic May Have New Use As Semaglutide Drugs Linked To Reduced Overdose Risk In Diabetic Opioid Users</a>
So, when the stock reversed and eventually returned to the support level, these remorseful sellers placed buy orders. And there were so many of these buy orders that it created support at the level which had been support before.
Seller's remorse&nbsp;can make support levels stay intact for an extended period of time.
When a stock drops to a support level, there is a tendency for them to reverse and rally. This is also because of psychology. It happens because some of the buyers experience anxiety.
These buyers are worried they will miss the trade. They know that the sellers will go to whoever is willing to pay the highest price.
As a result, they increase the prices they are willing to pay. Other anxious buyers see this and do the same thing.
This results in a bidding war that pushes the price higher.
If understood and interpreted correctly, technical analysis is the study of investor and trader psychology. Seller's remorse can cause support levels to stay intact for an extended period of time. Buyer's anxiety can make stocks rally after the drop to support levels.
Read Next: • <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/41028913/bristol-myers-2seventy-bio-halt-phase-3-trial-for-abecma-in-newly-diagnosed-myeloma">Bristol Myers-2seventy Bio Halt Phase 3 Trial For Abecma In Newly Diagnosed Myeloma Patients, Speeds Path To Profitability</a>
Photo: Shuttersotck

Technicals

Lose Weight With Novo Nordisk Drugs, Gain Money With Stock

Offerings

ASNS

Actelis Networks Entered Into At Market Offering Agreement; May Issue, Sell Shares Of Common Stock Of Up To $3.4M From Time To Time

UBS Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBS#NYSE">UBS</a>) has outperformed the market over the past 5 years by 7.69% on an annualized basis producing an average annual return of 21.91%. Currently, UBS Gr has a market capitalization of $96.19 billion. 
Buying $100 In UBS: If an investor had bought $100 of UBS stock 5 years ago, it would be worth $265.25 today based on a price of $30.00 for UBS at the time of writing.
<h3>UBS Gr's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727299820_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 5 Years Ago Would Be Worth $300 Today

TJX Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TJX#NYSE">TJX</a>) has outperformed the market over the past 15 years by 6.53% on an annualized basis producing an average annual return of 18.56%. Currently, TJX Companies has a market capitalization of $133.24 billion. 
Buying $100 In TJX: If an investor had bought $100 of TJX stock 15 years ago, it would be worth $1,271.92 today based on a price of $118.13 for TJX at the time of writing.
<h3>TJX Companies's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727299815_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In TJX Companies 15 Years Ago Would Be Worth Today

GOVX

GeoVax Labs May Offer & Sell Shares Of Common Stock With Offering Price Of Upto $4.4M From Time To Time Through Or To A.G.P.

Several chip stocks are moving higher after the market close on Wednesday alongside Micron Technology Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>), which jumped after the company reported <a href="https://www.benzinga.com/news/earnings/24/09/41034733/micron-q4-earnings-revenue-eps-beat-on-robust-ai-demand-company-sees-significantly-improved-profita">strong quarterly results</a>.
What Happened With MU: Micron beat analyst estimates on the top and bottom lines, reporting revenue of $7.75 billion versus <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">estimates</a>&nbsp;of $7.635 billion, and earnings of $1.18 per share versus estimates of $1.13 per share.
Micron said its 93% revenue growth in the quarter was driven by robust <a href="http://benzinga.com/topic/ai">AI</a> demand, which was the main driver of chip stock appreciation in recent years.
The memory-chip giant also guided for &#8220;significantly improved profitability&#8221; in fiscal 2025, which appears to be sparking the surge in shares. Micron stock was up 13.2% at $108.37 at the time of writing, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Don&#8217;t Miss: <a href="https://www.benzinga.com/news/earnings/24/09/41034733/micron-q4-earnings-revenue-eps-beat-on-robust-ai-demand-company-sees-significantly-improved-profita">Micron Q4 Earnings: Revenue, EPS Beat On &#8216;Robust AI Demand,&#8217; Company Sees &#8216;Significantly Improved&#8217; Profitability Ahead, Shares Surge</a>
Why It Matters: Micron focuses on making memory chips. Other big players in the semiconductor memory market like Western Digital Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>) and Lam Research Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>) are seeing the biggest gains after the bell, with both up more than 4% in after-hours trading at the time of writing, per <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Other chipmakers making moves after the bell include NVIDIA Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), Advanced Micro Devices Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>), Marvell Technology Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>), Taiwan Semiconductor Manufacturing Company Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) and Arm Holdings Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>). Several chip stocks were up roughly 1% after hours at last check.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/top-stories/24/09/41033617/voo-vs-vti-vanguards-s-p-500-total-stock-market-etfs-hit-new-highs-as-s-p-500-reaches-record-level">VOO Vs. VTI: Vanguard&#8217;s S&amp;P 500, Total Stock Market ETFs Hit New Highs As S&amp;P 500 Reaches Record Level</a></li>
</ul>
Photo: Courtesy of Arm Holdings.

Tech

LRCX

MRVL

NVDA

Western Digital, Nvidia, Other Chip Stocks Are Rising Wednesday: What's Behind The Move?

Macro Economic Events

Economics

Federal Reserve

Fed's Kugler Says Fed Funds Rate Determines Policy; Balance Sheet Shrinking Is Not A Key Part Of Achieving Mandates; We Are Not Celebrating, We Are Not There Yet, On 2% Inflation Goal

Free Cash Flow before Growth (FCFbG) guidance increased to $1,975 million - $2,125 million from $1,825 - $2,075 million, representing a midpoint increase of $100 million.

NRG Energy Lifts FY24 Adjusted EBITDA Guidance From $3.30B - $3.55B To $3.525B - $3.675B

A leading player in psychoactive hemp-derived products (PHDs), LFTD Partners Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LIFD#OTC">LIFD</a>) is trading at just 0.2x CY24 EV/Sales, offering a steep discount. The stock has plummeted over 90% from its April 2021 peak but remains cash flow positive with a net cash position, leaving the company ripe for expansion through mergers and acquisitions. 
Despite regulatory pressures, LIFD's compliant strategy is expected to drive market share gains. According to a report from Zuanic &amp; Associates, the stock could see a 5x rise by December 2025.
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. You can&#8217;t afford to miss out if you're serious about the business.</li>
</ul>
<h3 class="wp-block-heading">Valuation And Growth Potential</h3>
LIFD trades at 0.2x CY24 EV/Sales, below its estimated liquidation value. <a href="https://www.benzinga.com/topic/pablo-zuanic">Zuanic&#8217;s report </a>suggests that if LIFD were to reach 0.5x sales on projected estimates, the stock could rise 5x by December 2025.&nbsp;
This makes the stock an attractive, albeit speculative, investment. The analyst assigns only a 10% probability to a scenario of a federal ban on PHDs, providing further support for the stock's upside potential. However, the future of LIFD is highly binary, driven by regulatory developments.
<h3 class="wp-block-heading">Regulatory Risks And Opportunities</h3>
LIFD's business has been heavily impacted by regulatory challenges at both the state and federal levels, with 19 states having banned <a href="https://www.benzinga.com/topic/hemp">PHDs</a> outright.&nbsp;
However, according to Zuanic, the upcoming<a href="https://www.benzinga.com/markets/cannabis/24/05/39006814/house-committee-approval-of-amendment-eliminating-90-of-hemp-dervied-products-could-drive-wedge-"> Farm Bill</a> is expected to delegate the regulation of PHDs to individual states, potentially allowing LIFD to capitalize on compliant strategies in states with strict regulations rather than outright bans.&nbsp;
This could lead to market share gains and top-line growth.
Zuanic notes that LIFD has the opportunity to benefit from collaboration with THC cannabis companies entering the PHD space, which could validate the compliant PHD market and lead to potential joint lobbying efforts.&nbsp;
The long-term regulatory convergence between PHDs and THC products is another potential upside.
Read Also:&nbsp;<a href="https://www.benzinga.com/markets/cannabis/24/09/40906131/this-is-life-or-death-families-of-disabled-children-panic-over-gov-newsoms-hemp-cbd-ban-and-eval">&#8216;This Is Life Or Death&#8217;: Families Of Disabled Children Panic Over Gov. Newsom&#8217;s Hemp CBD Ban And Evaluate Lawsuit</a>
<h3 class="wp-block-heading">Bull Vs. Bear Case</h3>
In the bull case, if the regulatory landscape clarifies and no state bans emerge in key markets, LIFD's EV/Sales multiple could return to a 0.5-1.0x range.&nbsp;
This would imply a substantial upside. In the bear case, if federal legislation leads to a ban on PHDs or the company's nutraceutical strategy fails, the stock could face a total loss in value. However, Zuanic assigns just a 10% probability to this worst-case scenario.
Read Next: <a href="https://www.benzinga.com/markets/cannabis/24/09/41012794/gov-newsoms-hemp-ban-goes-into-effect-consequences-for-industry-investors-patients">Gov. Newsom&#8217;s Hemp Ban Goes Into Effect: Consequences For Industry, Investors, Patients</a>

Initiation

Analyst Ratings

LIFD

LIFD's 5x Potential: Is This Psychoactive Hemp Stock The Next Big Speculative Buy?

QRTEA

Qurate Retail Entered Into Call Agreement With Gregory B. Maffei, Executive Chairman Of Co; Pursuant To Deal, Gregory B. Maffei Granted To Co Right To Purchase All Shares Of High Vote Stock Owned By Maffei Upon His Death

WIIM

Pagaya Technologies shares are trading lower after the company announced its intention to offer $125 million of exchangeable senior notes due 2029 in a private offering.

&nbsp;The initial Annual Meeting occurred on&nbsp;September 25, 2024, at&nbsp;9AM ET&nbsp;and did not meet quorate and thus was adjourned for one week. We encourage Bit Digital shareholders to vote on the proposals.

BTBT

Bit Digital Adjourns Annual General Meeting Until October 2, 2024

Hugo Boss AG (BOSSY) Q2 2024 Earnings Call Transcript

In a report released on August 1, Jurgen Kolb from Kepler Capital maintained a Buy rating on Hugo Boss (0Q8F – Research Report), with a price targe...

Hugo Boss (0Q8F) Gets a Buy from Kepler Capital

Hugo Boss sells Russian business to wholesale partner Stockmann - report

In a report released today, Richard Chamberlain from RBC Capital maintained a Buy rating on Hugo Boss (0Q8F – Research Report), with a price target...

RBC Capital Remains a Buy on Hugo Boss (0Q8F)

Abercrombie & Fitch's (ANF) outstanding first-quarter results demonstrate the strength of its brands and the effective execution of its global strategy. Explore if the specialty retailer's solid brand momentum, cost optimization efforts, and upbeat growth outlook make it an attractive addition to your portfolio. Read on to know more... Abercrombie &amp; Fitch Co. (<a href="https://stocknews.com/stock/ANF/">ANF</a>) is a leading global specialty retailer specializing in apparel and accessories for kids through millennials. The company operates under the Abercrombie &amp; Fitch and Hollister brands, delivering high-quality, comfortable products catering to diverse lifestyle needs.
ANF operates more than 750 stores across North America, Europe, Asia, and the Middle East, as well as the e-commerce sites abercrombie.com and HollisterCo.com. The retailer's outstanding first-quarter 2024 results reflect the power of its brands and the solid execution of its global playbook.
The company reported first-quarter net sales of $1.02 billion, surpassing analysts' estimate of $964.99 million. ANF successfully managed seasonal transitions with relevant assortments and engaging marketing, leveraging agile chase capabilities and inventory discipline, which led to sales exceeding its expectations.
Sales growth was broad-based across regions and brands, with Abercrombie brands achieving a 31% increase and Hollister brands seeing a 12% rise. The robust top-line performance and gross profit expansion resulted in record first-quarter operating income and an operating margin of 12.7%. Its EPS came in at $2.14, compared to the consensus estimate of $1.72.
After a solid first-quarter performance, ANF <a href="https://corporate.abercrombie.com/investors/news-and-events/news/news/?id=24906">raised its full-year sales and operating margin outlook</a>. For fiscal 2024, the company expects net sales to be up nearly 10% from $4.3 billion in 2023. That is compared to the prior outlook of growth in the range of 4% to 6%. Its operating margin is expected to be around 14%, up from the previous outlook of nearly 12%.
For the second quarter of 2024, the omnichannel specialty retailer expects net sales growth to be up mid-teens compared to the second-quarter 2023 level of $935 million. ANF's operating margin is expected to be in the range of 13% to 14%, compared to 9.6% in the second quarter of 2023.
"We remain on track to achieve our 2024 goal of demonstrating sustainable, profitable growth after a defining year for the company in fiscal 2023. Our brands are delivering high-quality, on-trend assortments for new and retained customers across regions and brands. Importantly, we continue to make strategic investments across stores, digital and technology to further strengthen the company in pursuit of our long-term ambition," said CEO Fran Horowitz.
Shares of ALLE have gained 11.7% over the past month and 12.8% over the past year to close the last trading session at $127.75.
Let's look at factors that could influence ANF's performance in the upcoming months.
Solid Financial Performance
For the first quarter that ended May 4, 2024, ANF's net sales increased 22.1% year-over-year to $1.02 billion. Its gross profit rose 32.9% from the year-ago value to $677.46 million. Its operating income came in at $129.85 million, up 281.8% year-over-year. Its <a href="https://www.investopedia.com/terms/a/adjusted-ebitda.asp">adjusted EBITDA</a> grew 125% from the prior year's quarter to $167.54 million.
Additionally, net income attributable to A&amp;F was $113.85 million, or $2.14 per share, increases of 587% and 192.1% from the prior year's period, respectively. The specialty retailer ended the first quarter with cash and cash equivalents of $864.20 million.
Favorable Analyst Estimates
Analysts expect ANF's revenue for the second quarter (ending July 2024) to grow 15.9% year-over-year to $1.08 billion. The consensus EPS estimate of $2.23 for the ongoing quarter indicates an improvement of 102.5% year-over-year. Further, the company has topped consensus revenue and EPS estimates in each of the trailing four quarters, which is impressive.
For the fiscal year ending January 2025, Street expects ANF's revenue and EPS to increase 11.2% and 55.3% from the previous year to $4.76 billion and $9.75, respectively. The company's revenue and EPS for the fiscal year 2026 are expected to grow 4.8% and 1.4% year-over-year to $4.99 billion and $9.89, respectively.
Remarkable Historical Growth
Over the past three years, ANF's revenue has grown at a CAGR of 9.3%, and its EBITDA has increased at a CAGR of 22.9%. Its net income and EPS have improved at impressive CAGRs of 35.3% and 43.3% over the same period, respectively. In addition, the company's levered free cash flow has grown at a CAGR of 14% over the same timeframe.
Accelerating Profitability
ANF's trailing-12-month gross profit margin of 64.07% is 73.8% higher than the 36.87% industry average. Likewise, the stock's trailing-12-month EBITDA margin of 16.29% is 42.6% higher than the industry average of 11.42%. Moreover, its trailing-12-month net income margin of 9.53% is 103.7% higher than the industry average of 4.68%.
Also, the stock's trailing-12-month ROCE, ROTC, and ROTA of 47.78%, 18.13%, and 14.32% are favorably compared to the industry averages of 11.68%, 6.22%, and 4.26%, respectively. Its trailing-12-month levered FCF margin of 12.30% is 129.6% higher than the industry average of 5.36%.
POWR Ratings Reflect Promise
ANF's sound fundamentals are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system. The POWR Ratings are calculated by taking into account 118 different factors, with each factor weighted to an optimal degree.
Our proprietary rating system also evaluates each stock based on eight distinct categories. ANF has an A grade for Quality, consistent with higher-than-industry profitability. It also has a B grade for Growth, in sync with outstanding financial performance in the last reported quarter and optimistic analyst estimates.
Within the B-rated <a href="https://stocknews.com/category/fashion-luxury/">Fashion &amp; Luxury</a> industry, ANF is ranked #8 out of 59 stocks.
Beyond what I have stated above, we have also given ANF grades for Momentum, Value, Sentiment, and Stability. Get all ANF ratings <a href="https://stocknews.com/stock/ANF/">here</a>.
Bottom Line
ANF demonstrates robust financial health and significant growth potential, as evidenced by its outstanding first-quarter results and upward revisions to its full-year sales and operating margin outlook. The specialty retailer is well-positioned for continued success with its strategic investments in stores, digital platforms, and technology.
Given its robust financials, high profitability, and bright growth outlook, ANF presents a compelling investment opportunity with substantial upside potential.
How Does Abercrombie &amp; Fitch Co. (ANF) Stack Up Against Its Peers?
While ALLE has an overall POWR Rating of B, investors could also check out these other stocks within the <a href="https://stocknews.com/category/fashion-luxury/">Fashion &amp; Luxury</a> industry with an A (Strong Buy) rating: H&amp;M Hennes &amp; Mauritz AB ADR (<a href="https://stocknews.com/stock/HNNMY/">HNNMY</a>), J. Jill, Inc. (<a href="https://stocknews.com/stock/JILL/">JILL</a>), and Hugo Boss AG (<a href="https://stocknews.com/stock/BOSSY/">BOSSY</a>).
To explore more A or B-rated fashion stocks, <a href="https://stocknews.com/category/fashion-luxury/">click here</a>.
What To Do Next?
43 year investment veteran, Steve Reitmeister, has just released his 2024 market outlook along with trading plan and top 11 picks for the year ahead.
<a href="https://report.stocknews.com/sign-up/stock-market-outlook-2024/?formplacement=artbotad_smo24_rep">2024 Stock Market Outlook &gt;</a>

<hr />
ANF shares rose $0.44 (+0.33%) in premarket trading Thursday. Year-to-date, ANF has gained 49.13%, versus a 9.81% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Mangeet Kaur Bouns</h2> <img src='https:/wp-content/uploads/2022/01/Mangeet-Kaur-Bouns_Image-4.jpg' style="float:left; padding:5px;width:125px;">Mangeet's keen interest in the stock market led her to become an investment researcher and financial journalist. Using her fundamental approach to analyzing stocks, Mangeet's looks to help retail investors understand the underlying factors before making investment decisions.<a href="https://stocknews.com/authors/?author=mangeet-kaurbouns">More...</a>The post <a href=https://stocknews.com/news/anf-hnnmy-bossy-jill-should-you-add-abercrombie-fitch-anf-to-your-portfolio/>Should You Add Abercrombie & Fitch (ANF) to Your Portfolio?</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

Should You Add Abercrombie & Fitch (ANF) to Your Portfolio?

In a report released today, Manjari Dhar from RBC Capital maintained a Buy rating on Hugo Boss (0Q8F – Research Report), with a price target of €48...

Hugo Boss (0Q8F) Receives a Buy from RBC Capital

Deckers Outdoor (DECK) is gearing up for a six-for-one stock split to attract more investors and boost liquidity. But with elevated valuation, is it the right time to buy DECK ahead of its stock split? Read on to find out... Deckers Outdoor Corporation (<a href="https://stocknews.com/stock/DECK/">DECK</a>), a leader in designing, marketing, and distributing innovative and comfortable footwear, apparel, and accessories, announced that its board <a href="https://ir.deckers.com/news-events/press-releases/press-release/2024/Deckers-Brands-Announces-Board-Approval-of-Six-for-One-Forward-Stock-Split/default.aspx">approved a six-for-one forward stock split</a>, effective September 16, 2024.
"The trading price of our common stock has risen significantly over the past several years as a result of our strong financial performance and the execution of our strategic plan. We believe effecting the forward stock split will make the shares of our common stock more affordable and attractive to a broader group of potential investors, including our employees, and increase the liquidity of the trading of the shares of our common stock," stated Dave Powers, President and CEO of DECK.
DECK released solid results to kick off the fiscal year 2025. The company reported first-quarter revenue of $825.35 million, exceeding analysts' expectations of $806.18 million. Its EPS came in at $4.52, compared to the consensus estimate of $3.47. HOKA and UGG continue to drive solid full-price demand worldwide by offering innovative products that resonate with consumers.
HOKA&#xAE; brand net sales increased 29.7% year-over-year to $545.2 million. UGG&#xAE; brand net sales rose 14% year-over-year to $223.0 million. With HOKA and UGG delivering outstanding first-quarter results, Deckers raised the outlook for the full fiscal year. It increased EPS guidance to the range of $29.75-$30.65.
The company continued to expect net sales to increase nearly 10% to $4.7 billion for the fiscal year 2025. Operating margin is expected to be in the range of 19.5% to 20%.
Shares of DECK have surged 4.4% over the past month and 31.5% year-to-date to close its last trading session at $895.37. However, the stock has declined 1.8% over the past six months.
Let's look at factors that could influence CRWD's performance in the upcoming months.
Robust Financials
During the first quarter that ended June 30, 2024, DECK's <a href="https://www.investopedia.com/terms/n/netsales.asp">net sales</a> increased 22.1% year-over-year to $825.35 million. Its gross profit rose 35.7% from the year-ago value to $470 million. Its income from operations grew 87.8% year-over-year to $132.81 million.
Further, the company's net income came in at $115.63 million and $4.52 per share, up 81.9% and 87.6% from the prior year's quarter, respectively. As of June 30, 2024, its total assets were $3.31 billion, compared to $3.14 billion as of March 31, 2024.
Solid Historical Growth
DECK's revenue has grown at a CAGR of 17.1% over the past three years. Its EBITDA has increased at a CAGR of 19% over the same period, and its levered free cash flow has grown at a CAGR of 19.4%. Furthermore, the company's net income and EPS have improved at CAGRs of 22.8% and 26.7% over the same timeframe, respectively.
Favorable Analyst Estimates
Analysts expect DECK's revenue for the second quarter (ending September 2024) to increase 9.9% year-over-year to $1.20 billion. The consensus EPS estimate of $7.30 for the current quarter reflects a 7.1% year-over-year improvement. Moreover, the company has topped consensus revenue and EPS estimates in each of the trailing four quarters.
In addition, Wall Street expects the company's revenue and EPS for the fiscal year (ending March 2025) to grow 12.2% and 9.5% from the previous year to $4.81 billion and $31.93, respectively. For the fiscal year 2026, CRWD's revenue and EPS are expected to increase 10.6% and 13.5% year-over-year to $5.32 billion and $36.25, respectively.
Elevated Valuation
In terms of forward non-GAAP P/E, DECK is trading at 28.04x, 79.2% higher than the industry average of 15.65x. Similarly, the stock's forward EV/Sales of 4.48x is 264.7% higher than the industry average of 1.23x. Its forward EV/EBITDA of 20.63x is 110% higher than the 9.83x industry average.
Also, the stock's forward Price/Sales and Price/Cash Flow multiples of 4.73 and 25.92 are significantly higher than the industry averages of 0.88 and 9.77, respectively.
Accelerating Profitability
DECK's trailing-12-month gross profit margin of 56.54% is 52% higher than the industry average of 37.19%. Likewise, its trailing-12-month EBITDA margin of 23.91% is 108.9% higher than the 11.45% industry average. Also, the stock's trailing-12-month net income margin of 18.29% is favorably compared to the industry average of 4.66%.
Additionally, the stock's trailing-12-month ROCE, ROTC, and ROTA of 41.87%, 28.38%, and 24.55% are considerably higher than the industry averages of 11.47%, 6.18%, and 4.17%, respectively.
POWR Ratings Reflect Uncertainty
DECK's mixed fundamentals are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of C, translating to a Neutral in our proprietary system. The POWR Ratings are calculated by considering 118 different factors, with each factor weighted to an optimal degree.
Our proprietary rating system also evaluates each stock based on eight distinct categories. DECK has an A grade for Quality, in sync with its high profitability relative to its peers. It has a B grade for Growth, consistent with its solid financial performance in the last reported quarter.
However, the stock has a D grade for Value, in sync with its higher-than-industry valuation. Also, DECK has a D grade for Stability. The stock's 60-month beta of 1.05 justifies its Stability grade.
DECK is ranked #41 out of 58 stocks in the B-rated <a href="https://stocknews.com/category/fashion-luxury/">Fashion &amp; Luxury</a> industry.
Beyond what I have stated above, we have also given DECK grades for Momentum and Sentiment. Get access to all the DECK ratings <a href="https://stocknews.com/stock/DECK/">here</a>.
Bottom Line
DECK's upcoming six-for-one stock split is expected to boost liquidity and attract a wider range of investors. However, high valuation compared to industry averages may limit the stock's short-term upside potential. So, investors should weigh the stock's current premium and volatility against its high profitability and growth trajectory before making a decision.
Amid this backdrop, waiting for a better entry point in DECK seems wise now.
Stocks to Consider Instead of Deckers Outdoor Corporation (DECK)
Given its near-term uncertain prospects, the odds of DECK outperforming in the weeks and months ahead are compromised. However, there are many industry peers with much more impressive POWR Ratings. So, consider these A (Strong Buy) or B (Buy) stocks from the <a href="https://stocknews.com/category/fashion-luxury/">Fashion &amp; Luxury</a> industry instead:
Hugo Boss AG (<a href="https://stocknews.com/stock/BOSSY/">BOSSY</a>)
J.Jill, Inc. (<a href="https://stocknews.com/stock/JILL/">JILL</a>)
Weyco Group, Inc. (<a href="https://stocknews.com/stock/WEYS/">WEYS</a>)
For exploring more A and B-rated fashion stocks, <a href="https://stocknews.com/category/fashion-luxury/">click here</a>.
What To Do Next?
Discover 10 widely held stocks that our proprietary model shows have tremendous downside potential. Please make sure none of these "death trap" stocks are lurking in your portfolio:
<a href="https://report.stocknews.com/free-report/10-stocks-to-sell/?formplacement=artbotad_10sell">10 Stocks to SELL NOW! &gt;</a>

<hr />
DECK shares were trading at $878.50 per share on Thursday afternoon, down $16.87 (-1.88%). Year-to-date, DECK has gained 31.43%, versus a 16.45% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Mangeet Kaur Bouns</h2> <img src='https:/wp-content/uploads/2022/01/Mangeet-Kaur-Bouns_Image-4.jpg' style="float:left; padding:5px;width:125px;">Mangeet's keen interest in the stock market led her to become an investment researcher and financial journalist. Using her fundamental approach to analyzing stocks, Mangeet's looks to help retail investors understand the underlying factors before making investment decisions.<a href="https://stocknews.com/authors/?author=mangeet-kaurbouns">More...</a>The post <a href=https://stocknews.com/news/deck-bossy-weys-jill-is-deckers-brands-a-buy-ahead-of-its-stock-split/>Is Deckers Brands a Buy Ahead of Its Stock Split?</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

Is Deckers Brands a Buy Ahead of Its Stock Split?

Hugo Boss: A True Luxury Brand In The Bargain Bin

In a report released today, Jörg Philipp Frey from Warburg Research maintained a Buy rating on Hugo Boss (0Q8F – Research Report), with a price tar...

Warburg Research Sticks to Its Buy Rating for Hugo Boss (0Q8F)

In a report released today, Frederick Wild from Jefferies maintained a Buy rating on Hugo Boss (0Q8F – Research Report), with a price target of €50...

Jefferies Sticks to Their Buy Rating for Hugo Boss (0Q8F)

BBRYF

BURBY

CPRI

DECK

HESAF

HESAY

HNNMY

HUGPF

JILL

LVMHF

LVMUY

MONRF

MONRY

RACE

WEYS

Press Releases

International companies to host live webcasts at Deutsche Bank's Depositary Receipts

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Comments

Hugo Boss

Hugo Boss (BOSSY) Forecast

Hugo Boss (OTC:BOSSY) Stock, Quote.Headers.trade-ideas